Artificial Intelligence
Anti-Infective Agents Market Size Worth $164.1Bn Globally, by 2028 at 3.19% CAGR – Exclusive Report by The Insight Partners
New York, July 13, 2022 (GLOBE NEWSWIRE) — The Insight Partners published latest research study on “Anti-Infective Agents Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Range, Route of Administration, Indication, Distribution Channel, and Geography,” the rising prevalence of targeted diseases and rising government support for research activities and clinical trials are driving the anti-infective agents market.
Download PDF Brochure of Anti-Infective Agents Market Size – COVID-19 Impact and Global Analysis with Strategic Developments at: https://www.theinsightpartners.com/sample/TIPRE00004201/
Anti-Infective Agents Market Report Scope & Strategic Insights:
| Report Coverage | Details |
| Market Size Value in | US$ 135.9 billion in 2022 |
| Market Size Value by | US$ 164.19 billion by 2028 |
| Growth rate | CAGR of 3.19% from 2022 to 2028 |
| Forecast Period | 2022-2028 |
| Base Year | 2022 |
| No. of Pages | 241 |
| No. Tables | 137 |
| No. of Charts & Figures | 88 |
| Historical data available | Yes |
| Segments covered | Type, Range, Route of Administration, Indication, and Distribution Channel |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country scope | US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Anti-Infective Agents Market: Competitive Landscape and Key Developments
Abbott; Allergan Plc.; Astellas Pharma Inc.; Merck & Co., Inc.; Bayer AG; Bristol-Myers Squibb Company; Boehringer Ingelheim International GmbH; F. HOFFMANN-LA ROCHE Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline plc.; and Novartis AG are the key companies operating in the anti-infective agents market.
Inquiry Before Purchase: https://www.theinsightpartners.com/inquiry/TIPRE00004201/
- In Oct 2022, Merck expanded its vaccine manufacturing facility in Elkton, VA.
- In Jun 2022, Merck’s VAXNEUVANCE drug for Prevention of Invasive Pneumococcal Disease in Infants and Children was approved by US FDA.
- In May 2022, group sales increased by 11% (10% in CHF) to US$ 17.12 billion in the first quarter of the year. This will encourage the company to make better investments and expand.
- In Feb 2022, Roche announced the expansion of the COVID-19 PCR portfolio to the cobas 5800 System, a recently launched molecular laboratory instrument, in countries accepting the CE mark. These include cobas SARS-CoV-2 Qualitative and cobas SARS-CoV-2 & Influenza A/B tests.
- In May 2022, the FDA lifted the clinical hold placed on the Gilead Sciences Investigational New Drug Application (IND) to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP).
- In Apr 2022, the FDA approved a supplemental new drug application of Gilead Sciences for Veklury (remdesivir) for the treatment of pediatric patients under 12 years with COVID-19.
- In Apr 2022, Sandoz, a Novartis Division, announced the extension of its collaboration agreement with Ares Genetics (Ares), aimed at driving cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR).
- In Apr 2022, Novartis announced the introduction of a new organizational structure and operating model designed to support the company’s innovation, growth, and productivity ambitions as a focused medicines company in the coming decade.
- In Apr 2021, Abbott launched an adult vaccination program for flu, typhoid, and more vaccines to safeguard people’s health. The program aimed to create awareness regarding immunization in adult populations.
- In Dec 2021, Merck and Ridgeback’s Molnupiravir Received US FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19
- In Jan 2021, Merck confirmed an agreement with UNICEF to establish the world’s first global Ebola vaccine stockpile with ERVEBO (Ebola Zaire Vaccine, Live). ERVEBO is a vaccine indicated for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older.
- In Jun 2021, Bayer launched Bepanthen Derma for wounded skin, medicated skincare ranges, and daily management of dry skin. It is an antiseptic cooling cream that prevents infection.
- In Jun 2021, Bayer’s Astepro, an antihistamine nasal spray for allergies for seasonal and year-round allergic rhinitis, was approved to be available over the counter in the U.S.
- In Dec 2021, Roche announced the launch of the first infectious disease tests on the cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. These include cobas HIV-1, cobas HBV, cobas HCV, cobas HIV-1/HIV-2 Qualitative, and the cobas omni Utility Channel kit. These launches expand the Roche Molecular portfolio offering by providing standardized performance and efficiencies across low, medium, and high volume molecular laboratory testing needs.
- In Dec 2021, Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutions
- In Jul 2021, Roche announced in Japan that the Ministry of Health, Labor, and Welfare had approved Ronapreve (casirivimab and imdevimab) for the treatment of patients with mild to moderate COVID-19 via intravenous infusion. This antibody combination was granted a Special Approval Pathway under articles 14-3 of the Pharmaceuticals and Medical Devices Act.
- In Aug 2021, Bayer acquired Vividion Therapeutics for US$ 1.5 billion. Through this acquisition, Bayer strengthens its drug discovery platform. Vividion’s technology has proven its applicability pre-clinically in oncology and immune-related diseases and has the potential to expand into additional indications.
- In May 2021, Novartis and Molecular Partners announced the start of the clinical trial EMPATHY, a Phase 2 and 3 study, to explore the use of its novel DARPin therapeutic candidate ensovibep for the treatment of COVID-19.
- In Sep 2021, Boehringer Ingelheim announced the long-term partnership with Lifebit Biotech to utilize artificial intelligence (AI) for the detection and early reporting of global disease outbreaks using real-world data harvested from scientific publications and other open sources. Utilizing the Lifebit REAL platform, insights into the latest infectious disease outbreaks allow R&D efforts to be prioritized accordingly.
- In Mar 2021, Gilead Sciences, Inc. acquired MYR GmBH for up to approximately US$ 1.90 billion in aggregate cash consideration. The acquisition provides Gilead with Hepcludex (bulevirtide), which was conditionally approved by the European Medicines Agency for the treatment of chronic hepatitis delta virus (HDV) in adults with compensated liver disease.
Have a question? Speak to Research Analyst: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00004201
The US healthcare system is witnessing massive investments and new product introductions. Further, the majority number of market players are engaged in business activities such as sales and research partnerships, innovation, and product approvals. For instance, in July 2020, Merck & Co. unveiled its plan to begin two large clinical trials in September of an experimental oral anti-viral therapy, MK-4482, for COVID-19. Similarly, in April 2020, Abbott launched its third test for COVID-19 and is shipping tests to hospitals across the US. This new test is a lab-based serology blood test for the discovery of the antibody IgG that detects if a person has had COVID-19.
In the US, the FDA has approved the emergency use authorization of experimental drugs. Clinical trials of remdesivir, monoclonal antibodies, interferons, ACE inhibitors, and hydroxychloroquine have all been registered in the US. Furthermore, pharmaceutical companies are making tremendous efforts to develop drugs and vaccines against SARS-CoV-2. AbbVie, Harbour BioMed (HBM), Utrecht University (UU), and Erasmus Medical Center (EMC) have entered into a collaboration to develop novel antibody therapeutics to prevent and treat COVID-19. Additionally, AbbVie is donating US$ 35 million to address the impact of the COVID-19 patients in underserved communities.
Avail Lucrative DISCOUNTS on “Anti-Infective Agents Market” Research Study: https://www.theinsightpartners.com/discount/TIPRE00004201/
Alexion Pharmaceuticals Inc., an American pharmaceutical company, initiated a global Phase 3 study to conduct research on ULTOMIRIS (ravulizumab-cwvz) in a subset of adults with COVID-19. Additionally, in January 2022, Gilead Sciences, a biopharmaceutical company developing anti-viral drugs, received FDA approval for a supplemental new drug application (sNDA) for Veklury (remdesivir) for the treatment of non-hospitalized adults with a high risk of progression to severe COVID-19, which may lead to hospitalization or death. Thus, growing efforts by governments and pharmaceutical & biotech companies to effectively manage the COVID-19 pandemic would propel the growth of the anti-infective agents market during the forecast period.
Anti-Infective Agents Market: Segmental Overview
Based on type, the anti-infective agents market is segmented into anti-bacterial, anti-viral, anti-fungal, and others. Anti-viral agents are drugs approved by the US Food and Drug Administration (FDA) for the treatment of viral infections. It typically targets distinct phases of the viral life cycle. Anti-viral medications can be used for prophylaxis, treatment, suppression, or overt disease. Several strategies are used to develop anti-viral agents, including direct-acting anti-viral that target enzymes, viral proteins, or nucleic acids; passive antibodies that neutralize circulating viruses; and drugs that target cellular proteins or processes essential for viral replication. At least half of the currently offered anti-viral agents are for the treatment of human immunodeficiency virus (HIV) infections. The other drugs are primarily used to treat herpes viruses, hepatitis B, hepatitis C, and respiratory viruses.
Directly Purchase Premium Copy of Anti-Infective Agents Market Growth Report (2022-2028) at: https://www.theinsightpartners.com/buy/TIPRE00004201/
Browse Adjoining Reports:
Anti-Infective Drugs Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type (RIDT, Viral Culture, DFA, Serological Assays); Application (Hospitals, Clinical Laboratories, Others), and geography
Anti-Infective Endotracheal Tube Market Forecast to 2028 – COVID-19 Impact and Global Analysis by Product Type ( Silver Coated Endotracheal Tube, Drug Coated Endotracheal Tube ); End-User ( Hospital, Medical Centers ) Type ( Plants, Animals, Microbes )
Generic Drugs Market Forecast to 2028 – Covid-19 Impact and Global Analysis – By Product Type ( Biosimilars, Super Generic and Simple Generic ); Application ( Anti-Infective Drugs, Anti-Arthritis Drugs, Anti-Cancer Drugs, Central Nervous System Drugs, Cardiovascular Drugs, Respiratory Drugs and Other Applications ); Distribution Channel ( Hospitals, Pharmacies, Private Clinics and Other Distribution Channels )
Pet Veterinary Drugs Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product Type (Anti-Infectives, Anti-Inflammatory, Parasiticides, Analgesics, Sedatives, Others); Route of Administration (Oral, Parenteral, Topical); End User (Veterinary Hospitals, Veterinary Clinics, Drug Stores)
Veterinary Drugs Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product (Anti-Infective Drugs, Anti-Inflammatory Drugs, Parasiticides, Others); Route of Administration (Oral Route, Parenteral Route, Topical Route); End User (Veterinary Hospitals, Veterinary Clinics, Others) and Geography
Anti-Viral Therapies Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Type (Generic Drugs, Branded Drugs); Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Protease Inhibitors, Others); Application (HIV, Hepatitis, Virus Influenza, Herpes, Other Applications) and Geography
Antiviral Drugs Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Mechanism of Action (Protease Inhibitors, Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Others); Application (Hepatitis, HIV, Influenza, Herpes, Coronavirus Infection, Others); Type (Branded, Generic); Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies) and Geography
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: [email protected]
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/anti-infective-agents-market
Artificial Intelligence
Simplilearn and Degreed Collaborate to Transform Workforce Development with AI-Enhanced Learning
SAN FRANCISCO, Oct. 2, 2024 /PRNewswire/ — Simplilearn, the world’s leading digital skills training provider, and Degreed, the innovative learning platform, today announced their strategic partnership to offer premier educational content and platform solutions that drive skills-based learning. This collaboration introduces Simplilearn as one of the first to join Degreed’s AI-Ready partner category, integrating Simplilearn’s extensive educational offerings with Degreed’s advanced learning solutions to deliver transformative learning experiences for individuals and enterprises.
Simplilearn has been at the forefront of digital skills training for over a decade, supporting professionals and organizations worldwide with holistic learning experiences that are instructor-led and hands-on. Their comprehensive range of high-quality courses in artificial intelligence, machine learning, cloud computing, data science, and digital marketing is now seamlessly integrated into the Degreed platform. This AI-powered integration equips Learning & Development (L&D) professionals with a more targeted curation experience, simplifying the creation of personalized learning plans and development pathways tailored to the evolving needs of their teams and organizations.
As technology rapidly transforms industries and reshapes job roles, the demand for advanced, practical training is at an all-time high. Degreed’s ‘AI-Ready’ partner category makes it easier for customers to discover, organize, and access relevant learning materials. Through this partnership, a comprehensive suite of courses and resources is more easily discoverable, empowering individuals and organizations to upskill and stay competitive in the fast-evolving tech landscape.
Leveraging AI, the platform will offer personalized course recommendations based on each learner’s background and experience. This intelligent approach ensures that training is relevant and aligned with individual career goals and organizational needs. Additionally, the collaboration offers access to over 700 live classes each month, keeping teams updated with the latest industry trends and technological advancements. Complementing these live sessions are more than 500 courses and role-based learning paths covering essential areas such as AI, cybersecurity, data science, and machine learning.
Mr. Krishna Kumar, Founder and CEO, Simplilearn, said, “Partnering with Degreed represents a pivotal moment in our journey at Simplilearn. This collaboration underscores our commitment to harnessing cutting-edge technology and tailored learning experiences. By integrating Degreed’s advanced AI capabilities with our industry-leading programs, we are poised to redefine how individuals and organizations approach skill development, ensuring a more agile and role-ready workforce.”
Mr. Max Wessel, co-CEO of Degreed, said, “Our partnership with Simplilearn shows our dedication to equipping professionals with the most relevant skills for today’s fast-paced technology landscape. By using AI to power the integration of Simplilearn’s top-tier courses into Degreed, we enhance our ability to offer personalized, precise, and high-impact learning experiences – helping organizations turn the talent they have into the talent they need.”
About Degreed:
Degreed is the enterprise learning company, offering the world’s leading experience platform to drive skill driven development. Degreed enables organizations to collect, understand, and build skills to develop a workforce that’s ready for anything. To learn more about Degreed, visit www.degreed.com.
About Simplilearn:
Founded in 2010 and based in San Francisco, California, and Bangalore, India, Simplilearn, a Blackstone portfolio company, is the world’s leading digital skills provider, enabling learners across the globe. Simplilearn offers access to world-class work-ready training to individuals and businesses worldwide. Simplilearn offers 1,500+ live classes each month across 150+ countries, impacting over 8 million learners globally. The programs are designed and delivered with world-renowned universities, top corporations, and leading industry bodies via live online classes featuring top industry practitioners, sought-after trainers, and global leaders. From college students and early career professionals to managers, executives, small businesses, and big corporations, Simplilearn’s role-based, skill-focused, industry-recognized, and globally relevant training programs are ideal upskilling solutions for diverse career or business goals.
For more information, please visit www.simplilearn.com/
Logo: https://mma.prnewswire.com/media/1100016/4169121/Simplilearn_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/simplilearn-and-degreed-collaborate-to-transform-workforce-development-with-ai-enhanced-learning-302265798.html
Artificial Intelligence
Multinational Auto Manufacturer to Insource Service Operations with 3CLogic’s Integrated AI and Contact Center Solution for ServiceNow CSM and ITSM
Leading conglomerate selects 3CLogic’s CCaaS offering, purpose-built for ServiceNow CSM and ITSM, as it insources service desk operations to streamline workflows and save millions in operating costs.
ROCKVILLE, Md., Oct. 2, 2024 /PRNewswire/ — 3CLogic, the leading AI and cloud contact center solution for ServiceNow®, today announced the integration of its AI and CCaaS capabilities by a leading auto manufacturer as it seeks to optimize its service desk operations. Leveraging the company’s existing investment in ServiceNow IT Service Management (ITSM) and Customer Service Management (CSM), the collaboration is expected to enhance productivity, improve issue resolution, and significantly reduce operating expenses.
Manufacturing tens of millions of vehicles and equipment annually, supported by a vast network of over 150,000 associates and affiliates, the organization faced challenges due to the limited insights and services provided by its outsourced contact center. Among the most impactful was the lack of integration to its back-office ServiceNow IT and Customer workflows, where the siloed structure negatively impacted the organization’s visibility into performance, process improvements, and service speed.
“We are delighted to support this strategic initiative,” explains Denis Seynhaeve, CEO at 3CLogic. “This is yet another example of a large enterprise organization eager to reclaim ownership of its internal and external support services to enable better experiences through automation, simplification of its technology stack, and tactical use of AI for better insights.”
3CLogic’s integrated AI and contact center solution with ServiceNow CSM and ITSM will deliver a number of capabilities, including AI-powered call transcription and sentiment analysis, automated agent performance and coaching, after-hours voicemail transcription, integrated SMS alerts & notifications, and consolidated reporting with ServiceNow’s native performance analytics. The insourcing of services and process efficiencies are expected to generate approximately $2.6 million in ROI within the first three years of deployment. In addition, the organization is exploring the consolidation of its HR service delivery to unify its operations further.
As the first and only ServiceNow-certified Advanced Platform CCaaS partner, 3CLogic displays a unique approach to streamlined employee and customer workflows for ServiceNow and is expected to discuss its latest AI and contact center capabilities for ServiceNow ITSM, CSM, HRSD, and source-to-pay at the upcoming World Forums in Dallas, TX, on October 8th, 2024, in Munich, Germany, on October 23rd, 2024, and in New York City, NY, on November 7th, 2024.
For more information, please contact [email protected].
About 3CLogic3CLogic transforms customer and employee experiences with its leading Cloud Contact Center and AI solutions purpose-built to enhance today’s leading CRM and Customer Service Management platforms. Globally available and leveraged by the world’s leading brands, its offerings empower enterprise organizations with innovative features such as intelligent self-service, generative and Conversational AI, agent automation & coaching, and AI-powered sentiment analytics – all designed to lower operational costs, maximize ROI, and optimize each interaction across IT Service Desks, Customer Support, Sales or HR Services teams. For more information, please visit www.3clogic.com.
Logo – https://mma.prnewswire.com/media/2458632/3clogic_logo_400_x_281__1_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/multinational-auto-manufacturer-to-insource-service-operations-with-3clogics-integrated-ai-and-contact-center-solution-for-servicenow-csm-and-itsm-302264354.html
Artificial Intelligence
Life Science Analytics Market to Hit USD 61.94 Billion by 2029 with 11.7% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., Oct. 2, 2024 /PRNewswire/ — The global life science analytics market is projected to grow from USD 35.69 billion in 2024 to USD 61.94 billion by 2029, at a robust CAGR of 11.7%. Key drivers include advancements in analytical technologies that streamline data management and enhance insights from diverse sources like clinical trials and electronic health records, alongside rising demands for precision medicine. However, challenges such as data privacy concerns and a shortage of skilled professionals hinder progress. Noteworthy collaborations, like those between TetraScience and Databricks, exemplify the trend towards leveraging AI for improved outcomes in drug development and clinical trials. North America leads the market, fueled by high healthcare expenditure and a focus on innovation, while descriptive analytics currently dominates the market segments. Overall, the life science analytics landscape is evolving rapidly, presenting both opportunities and challenges that stakeholders must navigate to enhance research and operational efficiencies.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174990653
Browse in-depth TOC on “Life Science Analytics Market”
455 – Tables54 – Figures385 – Pages
Artificial Intelligence (AI) and Machine Learning (ML) are revolutionizing life science analytics by enabling advanced data analysis, pattern recognition, and predictive modeling, which are crucial for enhancing drug discovery, clinical trials, and personalized medicine. Companies are investing in leveraging AI & ML across their product lifecycles. In February 2024, Trinity Life Sciences launched Brand Insights AI, a new tool designed to enhance biopharmaceutical brand research by ingesting data from various sources, accelerating analysis, and revealing hidden patterns. This powerful tool leverages Trinity’s AI expertise to refine insights and optimize the use of existing information, supporting impactful and efficient research across the pharmaceutical commercialization spectrum.
The global life science analytics market is segmented into descriptive, prescriptive, and predictive analytics, by type. The prescriptive analytics segmented is expected to register highest growth during the forecast period. The high growth of this market is. driven by its ability to offer actionable recommendations, optimize decision-making, and streamline complex processes such as clinical trial management and personalized medicine. Its advanced predictive capabilities help stakeholders minimize risks, enhance treatment outcomes, and improve operational efficiency. Additionally, the excrubating demand for precision medicine and real-time data-driven strategies further fuels its adoption.
The life science analytics market is divided into services, and software, by component. In 2023, the largest share of life science analytics market belonged to the services segment. The high adoption of life science analytics services over software is driven by the need for specialized expertise and tailored solutions that go beyond the capabilities of standalone software. Increased security, improved cost effectiveness, better usability & flexibility, and improved integration capabilities of services are a few factors impacting market growth. Moreover, the escalating user base and changing needs of companies looking for all-inclusive solutions and support, coupled with the adoption of life science analytics software, generate demand for a range of services, including modification, implementation, and consulting.
The surging adoption of advanced analytics in commercial operations within the life sciences sector is revolutionizing how companies cultivate market strategies & enhance business performance to optimize product launches by providing insights into market trends, competitive landscapes, and customer preferences. Companies are leveraging various organic & inorganic strategies to expand their offerings in commercial operations. For instance, in April 2024, IQVIA and Salesforce expanded their global strategic partnership to accelerate the development of Salesforce’s Life Sciences Cloud, a next-generation customer engagement platform. This collaboration will combine IQVIA’s Orchestrated Customer Engagement (OCE) platform with Salesforce’s CRM, offering an end-to-end solution for transforming healthcare professional and patient engagement in the life sciences industry.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=174990653
The prominent players operating in the Life science analytics market include Oracle (US), Merative (formerly IBM) (US), SAS Institute (US), Accenture (Ireland), IQVIA (US), Cognizant (US), Wipro (India), Veradigm (US), Optum (US), Microsoft (US), MaxisIT (US), ExlService Holdings (US), Inovalon (US), CitiusTech (US), Saama (US), Axtria (US), Clarivate (UK), ThoughtSphere (US), ThoughtSpot (US), Salesforce (US), Google LLC (US), Amazon Web Services, Inc. (US), Veeva Systems (US), Elsevier (Netherlands), and Komodo Health, Inc. (US). These companies adopted strategies such as product launches, product updates, expansions, partnerships, collaborations, mergers and acquisitions to strengthen their market presence in the life science analytics market.
These players not only have a comprehensive and diverse product portfolio but also a strong geographic presence. Owing to the emergence of new application areas for life science analytics, these players can focus on technologies and offerings dedicated towards research & development, commercial operations, safety, etc.
These market players have offered a diverse range of products and services and have operations worldwide. They rely on technological advancements to avail themselves of innovative products and services and increase their global footprint. These players focus on acquisitions, collaborations, agreements, mergers, product launches & updates, partnerships, expansions, and other recent developments to expand their global reach and develop advanced life science analytics solutions.
Oracle (US) is one of the leading life science analytics companies across the globe. The company provides analytics software & services for various applications including research & development, commercialization, among others. The company focuses on continuously updating its products and meeting customer expectations. Oracle also continuously invests in expanding its solutions by partnerships & collaborations to provide tailored solutions to its end users. For instance, in February 2024, Oracle partnered with ObvioHealth, Inc. to integrate diverse data in decentralized clinical trials and analyze health data from several sources for clinical trials anywhere globally. The company holds a broad customer base and a wide geographic presence, making Oracle as a critical player in various IT software, hardware, and service-related markets, including the life science analytics market.
Merative (US) is one of the prominent players operating in the life science analytics market. Merative offers a comprehensive suite of informatics products and services for life science analytics. The company leverages advanced technologies such as artificial intelligence (AI), machine learning (ML), and other technologies to strengthen the accuracy and efficiency of evidence analysis. The company has a strong brand recognition and extensive product portfolio that has contributed to its success. The company serves life science systems, clinical trial sponsors, and medical device manufacturing industries. The company has established offices across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
For more information, Inquire Now!
Related Reports:
Healthcare Analytics Market
Healthcare IT Market
Telehealth Market
Remote Patient Monitoring Market
Clinical Decision Support Systems Market
Get access to the latest updates on Life Science Analytics Companies and Life Science Analytics Market Size
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected] Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original content:https://www.prnewswire.co.uk/news-releases/life-science-analytics-market-to-hit-usd-61-94-billion-by-2029-with-11-7-cagr–marketsandmarkets-302263498.html
-
Artificial Intelligence5 days agoCluePoints Launches Medical & Safety Review (MSR) Software to Revolutionize Clinical Data Review
-
Uncategorized5 days agoMC Digital Realty wins Frost & Sullivan’s 2024 Japan Data Center Services Company of the Year Award
-
Artificial Intelligence5 days agoHyperlink InfoSystem Takes the Spotlight as a Top AI Development Company in USA 2024
-
Uncategorized5 days ago
Prime Minister concludes successful visit from President of France to Canada
-
Artificial Intelligence5 days agoHow AIoT shapes the future of mobility: Hikvision at ITS World Congress 2024
-
Artificial Intelligence4 days agoHuawei Wen Tong: 6G Needs to Embrace AI for Shaping Future Network
-
Artificial Intelligence5 days agoAnti-Drone Market worth $7.05 billion by 2029 – Exclusive Report by MarketsandMarkets™
-
Artificial Intelligence5 days agoWondershare to Showcase Enterprise Solution Excellence at GITEX GLOBAL 2024
